Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/44192
Título : Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Autor : Buendía Rodríguez, Jefferson Antonio
Guerrero Patiño, Diana
Sánchez Caraballo, Jorge Mario
metadata.dc.subject.*: Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
Óxido Nítrico
Nitric Oxide
Análisis Costo-Beneficio
Cost-Benefit Analysis
Esputo
Sputum
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D000089142
https://id.nlm.nih.gov/mesh/D009569
https://id.nlm.nih.gov/mesh/D003362
https://id.nlm.nih.gov/mesh/D013183
Fecha de publicación : 2022
Editorial : BMC (BioMed Central)
Citación : Buendía JA, Guerrero Patiño D, Sánchez Caraballo JM. Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis. BMC Pulm Med. 2022 Jun 28;22(1):257. doi: 10.1186/s12890-022-02027-6.
Resumen : ABSTRACT: Introduction: Previous evidence has shown that fractional exhaled nitric oxide (FeNO) and eosinophil count in induced sputum (EO) are cost-effective relative to standard of care in guiding the management of children with persistent asthma. There is some doubt as if there are differences between these two biomarkers in terms of costs and benefits. Clarifying this doubt would allow prioritization of the design of clinical practice guidelines. The study aimed to compare in terms of costs and benefits these biomarkers in patients with asthma between 4 and 18 years of age. Methods: A Markov model was used to estimate the cost-utility of asthma management using FeNO and EO in patients between 4 and 18 years of age. Transition probabilities, cost and utilities were estimated from previously published local studies, while relative risks were obtained from the systematic review of published randomized clinical trials. The analysis was carried out from a societal perspective. Results: The expected annual cost per patient with EO was US $1376 (CI 95% US $1376-US $1377) and for FeNO was US $1934 (CI 95% US $1333-US $1334), with a difference of US $42.3 between these strategies. The Quality-adjusted life years (QALYs) per person estimated with EO was 0.95 (CI 95% 0.951-0.952) and for FeNO was 0.94 (CI 95% 0.930-0.940), with a difference of 0.01 between these strategies. The NMB with EO was US $4902 (CI 95% 4900-4904) and for FeNO was US $4841 (CI 95% 4839-4843). The incremental cost-effectiveness ratio of EO was $3566 per QALY gained regarding FeNO. Conclusion: Our study demonstrates that induced sputum-guided management is a strategy cost-effective over FeNO and standard asthma management in Colombia. This evidence should encourage the adoption of any of these techniques to objectively guide the management of children with asthma in routine clinical practice in low-resource settings.
metadata.dc.identifier.eissn: 1471-2466
metadata.dc.identifier.doi: 10.1186/s12890-022-02027-6
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
BuendiaJefferson_2022_Fractional_Exhaled_Nitric_Oxide.pdfArtículo de investigación1.01 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons